The use of recombinant or natural interferon alfa for the treatment of hematologic malignancies (lymphomas, leukemias, or plasma-cell malignancies) is medically necessary in off-label use for:
· first-line treatment of patients with Philadelphia chromosome-positive CML in first chronic phase;
· as a component of first-line treatment of patients with multiple myeloma, or as maintenance therapy of patients with multiple myeloma that has responded to first-line therapy;
· a combination with cytotoxic agents as first-line therapy of aggressive low-grade (follicular) or intermediate-grade non-Hodgkin’s lymphoma.
